The estimated Net Worth of George J Morrow is at least 25.7 百万$ dollars as of 17 May 2024. Mr. Morrow owns over 4,199 units of Neurocrine Biosciences stock worth over 510,053$ and over the last 21 years he sold NBIX stock worth over 24,626,850$. In addition, he makes 528,600$ as Independent Director at Neurocrine Biosciences.
George has made over 20 trades of the Neurocrine Biosciences stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 4,199 units of NBIX stock worth 510,053$ on 17 May 2024.
The largest trade he's ever made was exercising 75,000 units of Neurocrine Biosciences stock on 22 October 2013 worth over 624,750$. On average, George trades about 4,009 units every 56 days since 2003. As of 17 May 2024 he still owns at least 4,199 units of Neurocrine Biosciences stock.
You can see the complete history of Mr. Morrow stock trades at the bottom of the page.
George J. Morrow serves as Independent Director of the Company. Mr. Morrow served as Executive Vice President, Global Commercial Operations at Amgen Inc., a global biotechnology company, from 2003 until his retirement in 2011. He joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing. His responsibilities included oversight of all commercial functions for Amgen’s broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr. Morrow held executive management and commercial positions within several subsidiaries of Glaxo Wellcome, including Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer of Glaxo Wellcome, Inc. (U.S.). Mr. Morrow currently serves on the board of directors of Align Technology, Inc., a global medical device company. He has previously served on the boards of Vical, Inc., Otonomy, Inc., Glaxo Wellcome, Inc., Human Genome Sciences, Inc., Safeway, Inc., National Commerce Bank, the John Hopkins School of Public Health, and the Duke University Fuqua School of Business. Mr. Morrow holds a B.S. in chemistry from Southampton College, Long Island University, an M.S. in biochemistry from Bryn Mawr College and an M.B.A. from Duke University. The continued service of Mr. Morrow on the Company’s Board of Directors is based on his extensive commercialization experience at Amgen, his broad executive experience at GlaxoSmithKline Inc., and his years of experience in corporate governance as a board member of several publicly traded companies. Mr. Morrow’s board experience, leadership experience and commercialization expertise prove valuable strategic insights to the Board of Directors.
As the Independent Director of Neurocrine Biosciences, the total compensation of George Morrow at Neurocrine Biosciences is 528,600$. There are 16 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of 9,450,830$.
George Morrow is 68, he's been the Independent Director of Neurocrine Biosciences since 2015. There are 1 older and 22 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
George's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Over the last 21 years, insiders at Neurocrine Biosciences have traded over 159,913,426$ worth of Neurocrine Biosciences stock and bought 103,400 units worth 589,660$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Partners L P/Ilbiotechnolog...、Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of 1,567,813$. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth 2,090,333$.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: